Clinical Trial Update: A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating safety and efficacy of IBI306, a PCSK9 monoclonal antibody, in Chinese subjects with homozygous familial hypercholesterolemia completed Phase…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• IBI306

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2, Phase 3 | Status: COMPLETED